By vgreene, 2 October, 2020 Weigh risk/benefit of opioids. Consider trial of low-dose slow-release morphine (5-10 mg bid) in adults—response seen in 1wk, but only 1/2 of pts may respond; d/c if no response in 1-2wk, per ERS.5 Codeine not recommended due to less predictability, drug
By vgreene, 2 October, 2020 If choosing empiric gabapentin trial, 1st discuss contraindications, risk/benefit; start 300 mg daily escalating to max tolerable dose of 1800 mg daily (divided into 2 doses). Reassess risk/benefit @ 6 mo before continuing, per ACCP.3 ERS supports gabapen
By vgreene, 2 October, 2020 Multimodal speech path/cough control tx trial recommended, by experienced practitioners3,5
